Insmed Incorporated (INSM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Insmed Incorporated (INSM) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How INSM Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $606.4M | 79.7% | -205.6% | -$1.28B | -$967.6M | -45% |
| FY 2024 | $363.7M | 76.4% | -241.5% | -$913.8M | -$705.8M | -45% |
| FY 2023 | $305.2M | 44% | -232.5% | -$749.6M | -$550.0M | -6.9% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring INSM)
- ✓Live walkthrough of INSM's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
INSM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +66.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INSM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INSM. Explore sector supply chains on /butterfly.
INSM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Insmed Incorporated (INSM)?
In FY 2025 (10-K), INSM converted $606.4M of revenue into a 79.7% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).